$22.650
-0.847 (-3.74%)收盤時
VOR 資訊
VOR 事件
Cash and Marketable Securities Reach $466.1 Million, Projected to Fund Operations into Early 2029
Cash, cash equivalents and marketable securities were $466.1 million as of June 30, 2026, which together with the $48.4 million net proceeds from at-the-market sales during July 2026, are projected to fund operations into early 2029.
Vor Bio Files to Sell 5.34M Shares of Common Stock
Vor Bio files to sell 5.34M shares of common stock for holders
Vor Bio Doses First Patient in SjD Trial
Vor Bio announced the dosing of the first patient in UPSTREAM SjD, a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating telitacicept in adult patients with active primary Sjogren's disease, formerly known as Sjogren's syndrome.
Vor Bio Sells 5,338,078 Shares at $14.05 Each
Vor Bio announced that it has entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at a price of $14.05 per share in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $75M, before deducting any offering-related expenses. Vor Bio did not engage a placement agent in connection with the private placement. The private placement is expected to close on or about March 30, subject to the satisfaction of customary closing conditions. The financing is led by new investor TCGX. Vor Bio intends to use the net proceeds from the private placement to advance the clinical development of telitacicept, including the ongoing global Phase 3 clinical trials for myasthenia gravis and primary Sjogren's disease, business development, and for working capital and general corporate purposes.
Galapagos Appoints Tania Philipp as CHRO
Galapagos (GLPG) announced the appointment of Tania Philipp as chief human resources officer, or CHRO, effective March 4. Philipp will also join the management committee. She succeeds Annelies Missotten, who will remain with the company through June 30, to ensure a transition. Most recently, she served as an executive human resources consultant at Vor Bio (VOR).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。